Advertisement
Screener

Corbus Pharmaceuticals Holdings, Inc. (CRBP) Net Cash Provided by (Used in) Investing Activities, Continuing Operations

1.9 / 5 stars · 29/75 Roast Me

Corbus Pharmaceuticals Holdings, Inc. Net Cash Provided by (Used in) Investing Activities, Continuing Operations

Corbus Pharmaceuticals Holdings, Inc. (CRBP) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of -$1.27 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-10.

Discontinued › Cash Flow › Investing Activities

us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2018-05-10

  • Corbus Pharmaceuticals Holdings, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2018-03-31 was -$1.27M.
  • Corbus Pharmaceuticals Holdings, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-12-31 was -$580.18K.
  • Corbus Pharmaceuticals Holdings, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-09-30 was -$45.43K.
  • Corbus Pharmaceuticals Holdings, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-06-30 was -$41.69K.
  • Corbus Pharmaceuticals Holdings, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2017 was -$707.43K.
  • Corbus Pharmaceuticals Holdings, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2016 was -$353.03K.
  • Corbus Pharmaceuticals Holdings, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2015 was -$114.04K.
  • Corbus Pharmaceuticals Holdings, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2014 was -$64.45K.
Period endNet Cash Provided by (Used in) Investing Activities, Continuing Operations 3 monthNet Cash Provided by (Used in) Investing Activities, Continuing Operations 6 monthNet Cash Provided by (Used in) Investing Activities, Continuing Operations 9 monthNet Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month
2018-03-31-$1.27M
10-Q · filed 2018-05-10
-$1.85M
derived: sum of 2 quarters · filed 2018-05-10
-$1.90M
derived: sum of 3 quarters · filed 2018-05-10
-$1.94M
derived: sum of 4 quarters · filed 2018-05-10
2017-12-31-$580.18K
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12
-$625.61K
derived: sum of 2 quarters · filed 2018-03-12
-$667.30K
derived: sum of 3 quarters · filed 2018-03-12
-$707.43K
10-K · filed 2018-03-12
2017-09-30-$45.43K
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08
-$87.11K
derived: sum of 2 quarters · filed 2017-11-08
-$127.25K
10-Q · filed 2017-11-08
-$223.26K
derived: sum of 4 quarters · filed 2018-05-10
2017-06-30-$41.69K
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09
-$81.82K
10-Q · filed 2017-08-09
-$177.83K
derived: sum of 3 quarters · filed 2018-05-10
-$247.70K
derived: sum of 4 quarters · filed 2018-05-10
2017-03-31-$40.13K
10-Q · filed 2018-05-10
-$136.15K
derived: sum of 2 quarters · filed 2018-05-10
-$206.01K
derived: sum of 3 quarters · filed 2018-05-10
-$327.84K
derived: sum of 4 quarters · filed 2018-05-10
2016-12-31-$96.02K
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12
-$165.88K
derived: sum of 2 quarters · filed 2018-03-12
-$287.71K
derived: sum of 3 quarters · filed 2018-03-12
-$353.03K
10-K · filed 2018-03-12
2016-09-30-$69.86K
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08
-$191.69K
derived: sum of 2 quarters · filed 2017-11-08
-$257.01K
10-Q · filed 2017-11-08
-$350.01K
derived: sum of 4 quarters · filed 2018-03-12
2016-06-30-$121.83K
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09
-$187.15K
10-Q · filed 2017-08-09
-$280.15K
derived: sum of 3 quarters · filed 2018-03-12
-$284.97K
derived: sum of 4 quarters · filed 2018-03-12
2016-03-31-$65.32K
10-Q · filed 2017-05-09
-$158.32K
derived: sum of 2 quarters · filed 2018-03-12
-$163.14K
derived: sum of 3 quarters · filed 2018-03-12
-$177.63K
derived: sum of 4 quarters · filed 2018-03-12
2015-12-31-$93.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12
-$97.81K
derived: sum of 2 quarters · filed 2018-03-12
-$112.31K
derived: sum of 3 quarters · filed 2018-03-12
-$114.04K
10-K · filed 2018-03-12
2015-09-30-$4.81K
derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-10
-$19.31K
derived: sum of 2 quarters · filed 2016-11-10
-$21.04K
10-Q · filed 2016-11-10
-$21.04K
derived: sum of 4 quarters · filed 2016-11-10
2015-06-30-$14.49K
derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-12
-$16.22K
10-Q · filed 2016-08-12
-$16.22K
derived: sum of 3 quarters · filed 2016-08-12
-$72.66K
derived: sum of 4 quarters · filed 2016-08-12
2015-03-31-$1.73K
10-Q · filed 2016-05-13
-$1.73K
derived: sum of 2 quarters · filed 2016-05-13
-$58.17K
derived: sum of 3 quarters · filed 2016-05-13
2014-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-28
-$56.44K
derived: sum of 2 quarters · filed 2016-03-28
-$64.45K
10-K · filed 2016-03-28
2014-09-30-$56.44K
derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-10
-$64.45K
10-Q · filed 2015-11-10
2014-06-30-$8.01K
10-Q · filed 2015-08-13

Similar stocks

Stock NameCountryMarket CapPE Ratio
Annexon, Inc. (ANNX)United States$0.147B-4.22
SPRUCE BIOSCIENCES, INC. (SPRB)United States$0.142B-2.89
Korro Bio, Inc. (KRRO)United States$0.141B-1.81
Atrium Therapeutics, Inc. (RNA)United States$0.140B
Curanex Pharmaceuticals Inc (CURX)United States$0.138B
TuHURA Biosciences, Inc./NV (HURA)United States$0.134B-4.88
Unicycive Therapeutics, Inc. (UNCY)United States$0.134B-3.70
NRX Pharmaceuticals, Inc. (NRXP)United States$0.131B-6.31
MEDICINOVA INC (MNOV)United States$0.130B-6.04
IMMUNIC, INC. (IMUX)United States$0.127B-1.88